HLB Pharmaceutical Co Dettes/EBITDA

Que fait HLB Pharmaceutical Co ? HLB Pharmaceutical Co., Ltd. generates revenue through the manufacturing and sale of biotechnology-based pharmaceutical products. The company produces and sells cimetidine tablets, rozatin tablets, rabeprazole tablets, rozatinplus tablets, mosapia tablets, and other ethical the counter (ETC) drugs, as well as gynobetadine vaginal suppositories and other over the counter (OTC) drugs. Additionally, HLB offers commissioned ETC drugs such as aceclofenac tablets and revotec tablets, and commissioned OTC drugs including L-carnitine tablets, elcatan tablets, and hepatine liquids. These products are sold to healthcare providers, pharmacies, and consumers through established distribution channels. The primary customer segments for HLB's products include healthcare institutions requiring ETC drugs for prescription use, retail pharmacies selling OTC medications, and individual consumers purchasing OTC products directly. The company's product portfolio targets both prescription and non-prescription markets, with ETC drugs typically distributed through medical channels and OTC drugs available through general retail outlets. HLB's focus on biotechnology-driven formulations positions it within the pharmaceutical sector serving diverse healthcare needs. HLB's revenue streams are derived from direct sales of its branded pharmaceutical products to healthcare providers and retail networks. The company's ETC drugs, such as cimetidine and rabeprazole tablets, are primarily sold to hospitals and clinics for prescription use, while OTC products like gynobetadine vaginal suppositories and L-carnitine tablets reach consumers through pharmacy chains and online platforms. Commissioned products further diversify revenue by leveraging partnerships for manufacturing and distribution without direct brand ownership. HLB Pharmaceutical Co est l'une des entreprises les plus populaires sur Eulerpool.